about
Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors.A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis.KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels.FISH analysis of PTEN in endometrial carcinoma. Comparison with SNP arrays and MLPA.Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies.CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation.Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancerTargeted therapies in gynecologic cancers and melanoma.Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism.Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model.Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels.Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma.Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia.Nuclear factor-κB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1α independent manner.Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.Smooth muscle cells orchestrate the endothelial cell response to flow and injury.Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma.L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.β-Catenin and cyclin D1 expression in Gli1-independent basal cell carcinomas.DcR1 expression in endometrial carcinomas.Erk1/2 activation in stromal fibroblasts from sporadic basal cell carcinomas.The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors.Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues.Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma.Gene expression microarray-based assay to determine tumor site of origin in a series of metastatic tumors to the ovary and peritoneal carcinomatosis of suspected gynecologic origin.Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer.Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer.Oral intake of genetically engineered high-carotenoid corn ameliorates hepatomegaly and hepatic steatosis in PTEN haploinsufficient mice.Biological Effects of Temsirolimus on the mTOR Pathway in Endometrial Carcinoma: A Pharmacodynamic Phase II Study.Immunohistochemical analysis of T-type calcium channels in acquired melanocytic naevi and melanoma.A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma.Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma.A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistryUsefulness of Negative and Weak–Diffuse Pattern of SDHB Immunostaining in Assessment of SDH Mutations in Paragangliomas and PheochromocytomasFGFR2 alterations in endometrial carcinoma
P50
Q31129981-F8DEAC5C-6BD7-4EB4-BCDE-7EF947E2FF50Q33882422-477009EA-DF55-4206-9B86-8DAF54854795Q34805471-A1F66C18-D829-4466-9A91-FFD6AE7D23E3Q34805622-1D6D5135-D3B0-4A35-86DA-D17CE21B3954Q36920910-2B10F845-345E-4060-AC19-341062938794Q37073822-F488B9A7-1FE2-4329-8630-04AB4FC80960Q37317141-4C800557-D97A-4802-8ADF-7F31940D0262Q37327347-7E723D8B-DA5E-4C05-A162-031E079F56E0Q37588464-6C1EE8C4-A21B-4129-B45E-B9CEAA261332Q38280833-FFA0A0D4-1F9F-4DAE-9201-1BC5CEEB582BQ38765021-E4F33FD6-1AF7-4C2B-B8FD-0686078EDBE8Q38785352-9202C0A9-FD25-4831-BD9B-D54C23199E1CQ38812830-03F92E7C-E397-4277-9965-8DE4762A9A69Q39004188-87AA5548-5951-4FC1-AAD9-A5D283CABFF6Q39032124-A5EDA2DA-D10D-469D-A01A-C5DE7E923FAFQ39406462-BD16D01B-6471-4302-9789-B3599935BEF7Q39549560-D818C5CB-3DCB-4993-A4F7-8D276430F477Q39568919-3FFDEC12-A339-4199-81D7-05D3A40D299DQ39874611-1D49B23D-2525-46CE-B036-26E0E6A3414CQ39977778-012E18B4-20C5-45BC-B25C-F2F2D492CAB9Q40629455-82102334-0E8E-45A0-B2DA-63923D12AB0EQ42446569-720A4D6C-04B8-490E-88C7-F2B6237B3F2FQ42463517-1D8F41CE-C1CE-4B4D-A72E-95E66D54C7C0Q42476986-68C78EE8-348A-4368-8E2C-8BB8823219A4Q43195406-2DED19DC-01C8-444B-8635-9F333667CDE1Q43720808-15466672-38CC-4945-A2FD-5A4CB8335D11Q44151101-A292D8C8-A91F-4365-B6B2-73FA0B638E4EQ44529091-B0759BD9-B447-4E89-982F-75A5F889310FQ45098785-9712986A-1921-4285-8277-A70338D3C187Q47198560-A2C45972-D201-4B48-B1ED-78743265AE57Q48640596-B7F110FC-8BF0-4471-AE20-543DB5A6573BQ51113485-3D54FA46-59AE-4333-933B-09CA2AD8C770Q51543774-BAB25B9A-BC93-4AA5-A3A7-F49F3F519BFFQ51722094-FD8D62B3-DC84-431C-AD7A-1DBADBFCF1AFQ51777015-103DF625-4C3B-4882-B8B0-96E97534AF4CQ53306718-1E4454D7-2A50-4EA1-828B-49E00C345CE7Q53321450-ED37FAB1-9C55-49D9-A744-0F1B729C7EBCQ59123108-9697C3E5-4BC4-4BAE-A6C2-27C41EC109E0Q59123110-1B2D7B23-CCC1-4A6D-AA54-0DA2074EF2C2Q59123115-A3AB81C6-ED05-4E24-A6E8-0B00E3883EF2
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maria Santacana
@ast
Maria Santacana
@en
Maria Santacana
@es
Maria Santacana
@nl
Maria Santacana
@sl
type
label
Maria Santacana
@ast
Maria Santacana
@en
Maria Santacana
@es
Maria Santacana
@nl
Maria Santacana
@sl
prefLabel
Maria Santacana
@ast
Maria Santacana
@en
Maria Santacana
@es
Maria Santacana
@nl
Maria Santacana
@sl
P106
P21
P31
P496
0000-0003-1975-2598